Decheng Capital China Life Sciences USD Fund III, L.P. - Sep 28, 2021 Form 4 Insider Report for Cue Health Inc. (HLTH)

Role: 10%+ Owner
Signature: DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P. By: DECHENG CAPITAL MANAGEMENT III (CAYMAN), LLC, General Partner, By: /s/ Xiangmin Cui, Manager
Stock symbol: HLTH
Transactions as of: Sep 28, 2021
Transactions value $: $0
Form type: 4
Date filed: 9/30/2021, 05:48 PM
Previous filing: Sep 23, 2021
Next filing: Sep 27, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Ownership	Footnotes
transaction	HLTH	Common Stock	+Conversion of derivative security		+8,192,468			8,192,468	Sep 28, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HLTH	Series C-1 Preferred Stock	-Conversion of derivative security	$0	-8,192,468	-100%	$0.00	0	Sep 28, 2021	Common Stock	8,192,468		Direct	F1, F2

Decheng Capital China Life Sciences USD Fund III, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id	Content
F1	On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
F2	The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.

Content

On September 28, 2021, the Series C-1 Preferred Stock automatically converted into Common Stock on a one-to-one basis without payment of further consideration upon the closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.

The shares are held directly by Decheng Capital China Life Sciences USD Fund III, L.P. (the "Fund"). Decheng Capital Management III (Cayman), LLC (the "GP") is the general partner of the Fund. Xiangmin Cui is the manager of the GP. Each of the Fund, the GP and Dr. Cui may be deemed to beneficially own the securities held by the Fund. Each of the Fund, the GP and Dr. Cui disclaim beneficial ownership of these securities, except to the extent of their respective pecuniary interests therein.